lipid-lowering therapy


Also found in: Acronyms.

lipid-lowering therapy

drugs, dietary and lifestyle regimes directed toward restoring blood lipids to normal levels
References in periodicals archive ?
Nonetheless, 40% of patients received no lipid-lowering therapy in the 3 months before the ASCVD event and 90% received no high-intensity statins.
A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia.
All T2DM patients of either gender with fasting lipid profile irrespective of receiving lipid-lowering therapy were included.
In any case, it makes sense to maintain a low-cholesterol diet and to consider lipid-lowering therapy, including statins or niacin.
Approximately one-third of the patients experienced levels of LDL-C that were less than 100 mg/dl - close to the recommended therapeutic goals- at some point during the study, and concomitant lipid-lowering therapy was modified in a subset of these patients during the safety phase.
Table 1 summarizes data for age, sex, body mass index, current smoking, and use of lipid-lowering therapy for these individuals (with and without diabetes) according to the time since the last meal.
Thirteen of the 23 patients were able to have their background lipid-lowering therapy reduced during the Safety Phase of the study (between Week 26 and Week 56).
After adjusting for age, hypertension, smoking, alcohol consumption, atrial fibrillation, lipid-lowering therapy, and--in women--hormone replacement therapy and menopausal status, the researchers found that women with triglycerides above 445 milligrams per deciliter (mg/dL) had a four-fold increased risk for stroke compared with women whose non-fasting triglycerides were below 90 mg/dL.
Furthermore, placebo recipients who cross over to lipid-lowering therapy in the open-label phases of the studies demonstrate survival benefits as well, but never attain the protection achieved by being randomized to active treatment earlier on, according to Dr.
4) Combination lipid-lowering therapy is therefore not routinely indicated and should only be initiated at specialist level.
This double-blind, placebo-controlled Phase III study was designed to test the efficacy and safety of adding mipomersen to stable lipid-lowering therapy.